Deutsche Bank Initiates Coverage on AtaiBeckley with 'Buy' Rating and $12 Price Target

Deutsche Bank initiates coverage on AtaiBeckley with a "Buy" rating and sets a price target of $12, implying 320% potential upside. Analysts highlight the company's lead programs for treatment-resistant depression and seasonal affective disorder, and note that upcoming Phase 2 data could provide near-term catalysts for the stock. The firm believes AtaiBeckley will become a leader in psychedelic medicine for mental health conditions.